arginyl-glycyl-aspartyl-serine and Neoplasms

arginyl-glycyl-aspartyl-serine has been researched along with Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akazawa, T; Inoue, N; Kodama, K; Matsumoto, M; Seya, T; Shime, H	1
De, P; Dey, N; Durden, DL; Garlich, JR; Kundra, V; Lu, Y; Miller, A; Mills, GB; Murali, R; Peng, Q; Peng, X; Shu, HK; Su, JD	1
Karpatkin, S; Klepfish, A; Nierodzik, ML	1

Reviews

1 review(s) available for arginyl-glycyl-aspartyl-serine and Neoplasms

Article	Year
Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thrombosis and haemostasis, 1995, Volume: 74, Issue:1 Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Blood Platelets; Carcinoma; Cell Adhesion; Cricetinae; Fibronectins; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Oligopeptides; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Thrombin; Tumor Cells, Cultured; von Willebrand Factor	1995

Article

Year

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.

Thrombosis and haemostasis, 1995, Volume: 74, Issue:1

Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Blood Platelets; Carcinoma; Cell Adhesion; Cricetinae; Fibronectins; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Oligopeptides; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Thrombin; Tumor Cells, Cultured; von Willebrand Factor

1995

Other Studies

2 other study(ies) available for arginyl-glycyl-aspartyl-serine and Neoplasms

Article	Year
Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion. Cancer science, 2010, Volume: 101, Issue:7 Topics: Adjuvants, Immunologic; Amino Acid Sequence; Animals; BCG Vaccine; Cell Adhesion; Cell- and Tissue-Based Therapy; Dendritic Cells; Immunotherapy; Ligands; Lipopeptides; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Oligopeptides; Tissue Engineering; Toll-Like Receptor 1; Toll-Like Receptor 2	2010
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer research, 2008, Jan-01, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Inhibitors; Humans; Mice; Mice, Inbred Strains; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Prodrugs; Xenograft Model Antitumor Assays	2008

Article

Year

Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion.

Cancer science, 2010, Volume: 101, Issue:7

Topics: Adjuvants, Immunologic; Amino Acid Sequence; Animals; BCG Vaccine; Cell Adhesion; Cell- and Tissue-Based Therapy; Dendritic Cells; Immunotherapy; Ligands; Lipopeptides; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Oligopeptides; Tissue Engineering; Toll-Like Receptor 1; Toll-Like Receptor 2

2010

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Cancer research, 2008, Jan-01, Volume: 68, Issue:1

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Inhibitors; Humans; Mice; Mice, Inbred Strains; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Prodrugs; Xenograft Model Antitumor Assays

2008